The AJMC® clinical page includes all the published content across AJMC.com, The American Journal of Managed Care® and Evidence-Based Oncology™ on a variety of specialties, including dermatology, cardiology, oncology, and rheumatology.
January 6th 2025
A study demonstrated that pre-transplant measurable residual disease (MRD) status is a strong prognostic factor for overall survival, disease-free survival, and relapse risk in patients with AML and MDS undergoing allogeneic stem cell transplantation.
Researchers Demonstrate Efficacy of EEG-Based Test for Measuring Pain
December 8th 2018Patients who visit the emergency department for pain are often asked to categorize their pain level using a visual scale of numbered faces. However, a recent study suggests the efficacy of a more empirical approach, through the use of an electroencephalography (EEG)-based test, that would be beneficial for both patients and physicians.
Read More
International Consensus on Timely Care for Multiple Sclerosis
December 7th 2018Multiple sclerosis (MS) is a progressive neurological disease that requires timely management, and a panel of neurologists has developed an internationally applicable standard of care for timely management in patients with MS.
Read More
Patients Who Stop Taking Gilenya May Experience Worsening of Multiple Sclerosis
December 4th 2018The FDA has issued a safety warning that patients who stopped taking Gilenya experienced worsening of multiple sclerosis, compared with before treatment started or during treatment, in rare cases.
Read More
Epigenetic Changes Are the Main Contributor to Immune Escape in Posttransplantation AML Relapse
December 1st 2018In patients who relapse after allogeneic hematopoietic stem-cell transplantation, the therapeutic benefits that transplantation provide is diminished through mechanisms that remain unclear. A new study analyzed the genetic and epigenetic alterations of leukemic cells to determine any common features of relapse after transplantation
Read More
FDA Approves 2 Treatments in Older Adults With Newly Diagnosed AML
November 27th 2018FDA has recently approved 2 new treatments for patients age 75 and older who are newly diagnosed with AML and have other chronic health conditions or diseases that may mean they cannot use intensive chemotherapy.
Read More